Encouraging preliminary data from the NEFIGAN trial suggest that a novel oral formulation of budesonide might reduce disease progression in IgA nephropathy. This formulation releases corticosteroid in the distal small intestine and colon, so is thought to directly target the mucosal element of the pathogenesis of the disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fellström, B. C. et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)30550-0 (2017).
Spurio, F. F. et al. Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter? J. Gastrointestin. Liver Dis. 22, 65–71 (2013).
Coppo, R. The gut–kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-017-3652-1 (2017).
Kidney Disease Improving Global Outcomes. KDIGO clinical practice guidelines for glomerulonephritis. Immunoglobulin A nephropathy. Kidney Int. Suppl. 2, 209–220 (2012).
Pozzi, C. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J. Am. Soc. Nephrol. 15, 157–163 (2004).
Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).
Lv, J., Zhang, H. & Perkovic, V. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study. Presented at the ERA-EDTA Meeting, Vienna, Austria, 2016 http://www.abstracts2view.com/era/view.php?nu=ERA16L1_3394&terms= (last accessed 4 May 2017).
Glassock, R. J. Moderator's view: treatment of IgA nephropathy-getting comfortable with uncertainty. Nephrol. Dial. Transplant. 31, 1776–1780 (2016).
Edsbäcker, S., Nilsson, M. & Larsson, P. A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone. Aliment. Pharmacol. Ther. 13, 219–224 (1999).
Mallipattu, S. K. et al. Kruppel-like factor 15 mediates glucocorticoid-induced restoration of podocyte differentiation markers. J. Am. Soc. Nephrol. 28, 166–184 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Glassock, R. Targeted steroid therapy for IgA nephropathy. Nat Rev Nephrol 13, 390–392 (2017). https://doi.org/10.1038/nrneph.2017.65
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.65
This article is cited by
-
Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria
International Urology and Nephrology (2020)
